Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | NRP1 | O14786 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL5035367 | 0.89 | GSR (0.43) | GSR | |
| Lysine SCHEMBL6139631 | 0.81 | GSR (0.36) | GSR | |
| SCHEMBL5035365 | 0.81 | TGM2 (0.45) | CPB2 | |
| SCHEMBL6862733 | 0.81 | GLP1R (0.33) | CPB2CA12CA1CA2CA9 | |
| SCHEMBL6139837 | 0.81 | C3AR1 (0.33) | CPB2CA12CA1CA2CA9 | |
| SCHEMBL5038355 | 0.81 | GLP1R (0.33) | CPB2CA12CA1CA2CA9 | |
| SCHEMBL5032641 | 0.75 | F2 (0.41) | CA1CA2 | |
| SCHEMBL6139756 | 0.74 | F2 (0.33) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL29051861 | 0.73 | FOLH1 (0.47) | CPB2FOLH1CA12CA1CA2 | |
| Trifluoromethanesulfonic Acid SCHEMBL28645196 | 0.73 | FOLH1 (0.47) | CPB2FOLH1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| US-6676928-B2 | AS CONTRAST MEDIA FOR THE VISUALIZATION OF MALIGNANT TUMORS, LYMPH NODES AND NECROTIC TISSUE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | SCHERING AG (DE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | CPB2 1933/4885FOLH1 2668/4885NRP1 1553/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | CPB2 2498/4885FOLH1 3271/4885NRP1 903/4885 |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | FFAR1, FGB, FCGRT | CPB2 2853/4885FOLH1 2292/4885NRP1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.